



Takeda Pharmaceutical Company Limited

1-1, DOSHOMACHI 4-CHOME, CHUO-KU, OSAKA 540-8645, JAPAN

News Release

Contact:

Corporate Communications Dept.

Tel: +81-3-3278-2037

Takeda to Obtain Development and Commercial Rights for R-851 from 3M

Investigational Compound for the Treatment for Cervical High-Risk HPV Infection

Osaka, Japan, March 30, 2007 --- Takeda Pharmaceutical Company Limited (“Takeda”) announced today that it has acquired the development and commercial rights to R-851 from 3M for topical cervical high-risk human papillomavirus (HPV) infection and cervical dysplasia. R-851 is an immune response modifier (IRM) and potential topical treatment for these indications. Under this new agreement, Takeda will obtain full rights for R-851 for these indications from 3M, while 3M will receive certain development milestones and a royalty once R-851 is successfully commercialized.

Discovered and developed by 3M, R-851 is part of the family of immune response modifier (IRM) molecules. IRMs act in a novel way to stimulate the human body’s immune system to fight virus-infected cells and tumor cells. R-851 is currently in Phase 2 clinical testing in the United States. In March 2005, Takeda and 3M signed an agreement to co-develop and jointly market R-851 in the United States and Europe. Takeda also was granted exclusive rights in Japan and certain Asian countries, while other territories were retained for 3M.

“We are very pleased with this new agreement,” said Yasuchika Hasegawa, President of Takeda. “We now have complete responsibility for the R-851 program, which expands our opportunity with this novel treatment for HPV infection. We will vigorously conduct development activities toward the earliest possible launch of the product so that we can offer this product to the women facing the risk for cervical cancer and the physicians who treat them.”

###

<About Takeda>

Located in Osaka, Japan, Takeda is a research-based global pharmaceutical company. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information is available in its corporate website, www.takeda.com.

###